Three EU Tecfidera Generics Recommended As Biogen Battles For Exclusivity
Mylan, Polpharma And Neuraxpharm Backed Amid Regulatory Tussle
Following a years-long back-and-forth to establish exclusivity protection for its Tecfidera multiple-sclerosis treatment in Europe, Biogen has ultimately seen the CHMP recommend three generic versions to receive pan-European marketing authorization.
